Pharmaceutical composition and health functional food containing extract of fruiting body of ganoderma lucidum as active ingredient for prevention or treatment of thrombosis
US-2024131098-A1 · Apr 25, 2024 · US
US11261419B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11261419-B2 |
| Application number | US-201916719630-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 18, 2019 |
| Priority date | Dec 19, 2018 |
| Publication date | Mar 1, 2022 |
| Grant date | Mar 1, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method for preparing a hyper-cellulolytic catabolite derepressed mutants of ascomycetes fungus, especially variants of Penicillium funiculosum. Selection media used to isolate such variants include amorphous cellulose and a high concentration of glucose. Cellulase activities of mutant ID-10, in particular such as FPase and β-glucosidase were 1.5 times higher than Penicillium funiculosum MRJ-16 (parent). Furthermore, fungal mutant morphology was changed and no pH adjustment was required throughout the enzyme production process.
Opening claim text (preview).
The invention claimed is: 1. A method of preparing a mutant fungal strain comprising: (a) preparing a mutant fungal strain by contacting Penicillium funiculosum MRJ-16 with an aerobic culture medium followed by treatment with UV light or N-methyl-N′-nitro-Nnitrosoguanidine (NTG) or ethyl methanesulfonate (EMS) mutagens or in combination; (b) screening for the mutant fungal strain having higher celluloytic activity as compared to the Penicillium funiculosum MRJ-16 by aerobic fermentation in an aerobic culture medium comprising amorphous cellulose and glucose at concentration of 1-4% (w/w) under conditions suitable for the production of enzymes; (c) obtaining a mutant fungal strain Penicillium funiculosum -ID-10; and (d) screening the efficiency of the enzyme produced by the mutant fungal strain Penicillium funiculosum -ID-10 by hydrolyzing biomass. 2. The method in of claim 1 , wherein the aerobic culture medium comprises 4% glucose. 3. The method in of claim 1 , wherein the fermentation in step (b) is carried in an aerated stirred tank having a glass jacketed vessel of 2 L and working volume of 1.8 L. 4. The method in of claim 1 , wherein the aerobic culture medium comprises ammonium sulphate 5 g/L, KH 2 PO 4 6 g/L, MgSO 4 *7H 2 O 1 g/L, CaCO 3 5 g/L, Glycerol 2.5 g/L, Corn steep solids 30 g/L, cellulose 30 g/L and Tween-80 2 ml/L. 5. The method of claim 1 , wherein the method is carried out in a fermenter, which was sterilized at 120° C. for 20 minutes and cooled at 30° C. along with maintaining pH of 5.5. 6. The method of claim 1 , wherein the enzyme produced in step (b) is a cellulase enzyme.
Calcium; Ca chelators; Calcitonin · CPC title
Processes using, or culture media containing, cellulose or hydrolysates thereof · CPC title
Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title
Fungi (culture of mushrooms A01G18/00; as new plants A01H15/00); Culture media therefor · CPC title
Magnesium; Mg chelators · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.